Real-World Outcomes of Transcatheter Tricuspid Valve Replacement

Q: What is the clinical evidence from this study?

Study design: Observational. Population: Tricuspid regurgitation (n=1034). Intervention: Transcatheter tricuspid valve replacement (TTVR). Primary outcome: Residual mild or less tricuspid regurgitation at 30 days.

Q: What does this research mean for the field?

Transcatheter tricuspid valve replacement in real-world practice achieves high procedural success with near elimination of tricuspid regurgitation and acceptable 30-day safety outcomes. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Rebecca T. Hahn; Rahul P. Sharma; George Petrossian; Robert J. Cubeddu; Santiago Garcia; Tiberio Frisoli; Samir Kapadia; Aakriti Gupta; Akhil Narang; Moody Makar; Mackram F. Eleid; Pradeep Yadav; Pedro Villablanca Spinetto; Martin B. Leon; Vasilis C. Babaliaros; Jeremiah P. Depta; John Paul Vavalle; Isida Byku; Jake Michael Chanin; Ratnasari Padang; Raj R. Makkar; Howard C. Herrmann; Joseph A. Sivak; Brian Patrick O’Neill; Christina Lalani; M. Andrew Morse; Tanvir K. Bajwa; Peter Flueckiger; James Lee; Yang Song; Sahil Khera; Patrick Gleason; Laura J. Davidson; Mathew Williams; Christiane Haeffele; Robert W. Yeh; Susheel Kodali; Alan Zajarías; Vinod Thourani; Charles J. Davidson; Gilbert Tang; Suhail Allaqaband

doi:10.17615/nmxw-wp57

Key result

TTVR achieves mild or less residual TR in ~98% of patients at 30 days.

n=1,034

Why the study?

The effectiveness, safety, and patient-reported outcomes of transcatheter tricuspid valve replacement (TTVR) in early US real-world registry experience required evaluation.

Does transcatheter tricuspid valve replacement (TTVR) improve effectiveness, safety, and patient-reported outcomes in US real-world patients?

Key Points

To evaluate the real-world effectiveness, safety, and patient-reported outcomes of transcatheter tricuspid valve replacement in early US clinical practice.
Analyzed early postapproval registry data from 1034 patients undergoing transcatheter tricuspid valve replacement across 82 US centers.
Tracked 30-day procedural success, residual regurgitation, and adverse clinical events including mortality, stroke, bleeding, and pacemaker implantation.
Valves were successfully implanted in 98.4% of patients, and 97.7% achieved residual mild or less tricuspid regurgitation at 30 days.
At 30 days, rates of all-cause death, stroke, and bleeding were 3.1%, 0.2%, and 7.9%, respectively.
A new cardiovascular implantable electronic device was required in 15.9% of patients who had no preexisting device.

Study Design

Type

Observational (n=1,034)

Multicenter

Yes

Structured PICO

Does transcatheter tricuspid valve replacement (TTVR) improve effectiveness, safety, and patient-reported outcomes in US real-world patients?

P

Population

1,034 patients undergoing transcatheter tricuspid valve replacement across 82 US centers, followed for 30 days.

E

Exposure

Transcatheter tricuspid valve replacement (TTVR)

O

Outcome

Effectiveness, safety, and patient-reported outcomes at 30 days (including valve implantation success, residual tricuspid regurgitation, all-cause death, stroke, bleeding, and need for a new cardiovascular implantable electronic device)

In the first year of commercial US experience, transcatheter tricuspid valve replacement demonstrated high procedural success and near-complete elimination of tricuspid regurgitation with acceptable 30-day safety outcomes, though with a notable rate of new pacemaker/device implantation.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

High procedural success supports TTVR feasibility; leaves open durability and outcome questions for prospective trials.

Abstract

Key Points Question: In early US real-world registry experience, what are the effectiveness, safety, and patient-reported outcomes of transcatheter tricuspid valve replacement (TTVR)? Findings: Among 1034 patients undergoing TTVR across 82 centers, a valve was successfully implanted in 98.4%, and residual mild or less tricuspid regurgitation was achieved in 97.7% of patients at 30 days. At 30 days, all-cause death was 3.1%; stroke, 0.2%; bleeding, 7.9%; and need for a new cardiovascular implantable electronic device among patients without a preexisting device was 15.9%. Meaning: In the first year after approval in the US, patients undergoing TTVR experienced acceptable early safety, near elimination of tricuspid regurgitation, and significant symptomatic and health status improvements.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hahn et al. (2026) conducted an observational in Tricuspid regurgitation (n=1,034). Transcatheter tricuspid valve replacement (TTVR) was evaluated on Residual mild or less tricuspid regurgitation at 30 days. Transcatheter tricuspid valve replacement achieved 98.4% implantation success, 97.7% mild or less residual TR, and 3.1% mortality at 30 days.

synapsesocial.com/papers/6ae28e56cbadf70daf6c41e3 https://doi.org/10.17615/nmxw-wp57

View Full Paper

Ask AI

Bookmark

Share

Real-World Outcomes of Transcatheter Tricuspid Valve Replacement

Key Points

Study Design

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Real-World Outcomes of Transcatheter Tricuspid Valve Replacement

Key Points

Study Design

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading